ixazomib and Colorectal-Neoplasms

ixazomib has been researched along with Colorectal-Neoplasms* in 2 studies

Other Studies

2 other study(ies) available for ixazomib and Colorectal-Neoplasms

Article	Year
Ixazomib promotes CHOP-dependent DR5 induction and apoptosis in colorectal cancer cells. Cancer biology & therapy, 2019, Volume: 20, Issue:3 Ixazomib (Ninlaro), a novel proteasome inhibitor, has been developed for the treatment of many cancers and has demonstrated anti-tumor efficacy against various malignancies. However, the mechanism of the anti-tumor effect of ixazomib in colorectal cancer (CRC) cells remains unclear.. MTS and flow cytometry were performed to determine the effect of ixazomib on CRC cells. Western blotting and real-time RT-PCR were performed to detect ixazomib-induced DR5 upregulation. ChIP was performed to detect CHOP binding to DR5 promoter. Finally, xenograft experiments were carried out to measure the antitumor effect of ixazomib in vivo.. In this study, we revealed the mechanism by which ixazomib inhibits the growth of CRC cells. Our findings indicated that ixazomib treatment induces CHOP-dependent DR5 induction, irrespective of p53 status. Furthermore, DR5 is necessary for ixazomib-mediated apoptosis. Ixazomib also synergized with TRAIL to induce marked apoptosis via DR5 in CRC cells.. Our findings further suggested that ixazomib sensitizes TRAIL/death receptor signaling pathway-targeted CRC and suggested that DR5 induction could be a valuable indicator of ixazomib sensitivity. Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boron Compounds; Cell Line, Tumor; Colorectal Neoplasms; Cyclophosphamide; Doxorubicin; Glycine; Humans; Prednisone; Receptors, TNF-Related Apoptosis-Inducing Ligand; Transfection; Vincristine	2019
Non-invasive imaging of disrupted protein homeostasis induced by proteasome inhibitor treatment using chemical exchange saturation transfer MRI. Scientific reports, 2018, 10-10, Volume: 8, Issue:1 Proteasome inhibitors (PIs) are now standard of care for several cancers, and noninvasive biomarkers of treatment response are critically required for early patient stratification and treatment personalization. The present study evaluated whether chemical exchange (CEST) magnetic resonance imaging (MRI) can provide measurements that can be used as the noninvasive biomarkers of proteasome inhibition, alongside diffusion MRI and relaxometry. The sensitivity of human colorectal carcinoma cells to the PI Ixazomib was assessed via in vitro and in vivo dose-response experiments. Acute in vivo response to Ixazomib was assessed at three dosing concentrations, using CEST MRI (amide, amine, hydroxyl signals), diffusion MRI (ADC) and relaxometry (T Topics: Amides; Amines; Animals; Apoptosis; Boron Compounds; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Diffusion Magnetic Resonance Imaging; Dose-Response Relationship, Drug; Female; Glycine; Humans; Image Interpretation, Computer-Assisted; Magnetic Resonance Imaging; Mice, Nude; Proteasome Inhibitors; Proteostasis; Tumor Burden; Xenograft Model Antitumor Assays	2018

Article

Year

Ixazomib promotes CHOP-dependent DR5 induction and apoptosis in colorectal cancer cells.

Cancer biology & therapy, 2019, Volume: 20, Issue:3

Ixazomib (Ninlaro), a novel proteasome inhibitor, has been developed for the treatment of many cancers and has demonstrated anti-tumor efficacy against various malignancies. However, the mechanism of the anti-tumor effect of ixazomib in colorectal cancer (CRC) cells remains unclear.. MTS and flow cytometry were performed to determine the effect of ixazomib on CRC cells. Western blotting and real-time RT-PCR were performed to detect ixazomib-induced DR5 upregulation. ChIP was performed to detect CHOP binding to DR5 promoter. Finally, xenograft experiments were carried out to measure the antitumor effect of ixazomib in vivo.. In this study, we revealed the mechanism by which ixazomib inhibits the growth of CRC cells. Our findings indicated that ixazomib treatment induces CHOP-dependent DR5 induction, irrespective of p53 status. Furthermore, DR5 is necessary for ixazomib-mediated apoptosis. Ixazomib also synergized with TRAIL to induce marked apoptosis via DR5 in CRC cells.. Our findings further suggested that ixazomib sensitizes TRAIL/death receptor signaling pathway-targeted CRC and suggested that DR5 induction could be a valuable indicator of ixazomib sensitivity.

Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boron Compounds; Cell Line, Tumor; Colorectal Neoplasms; Cyclophosphamide; Doxorubicin; Glycine; Humans; Prednisone; Receptors, TNF-Related Apoptosis-Inducing Ligand; Transfection; Vincristine

2019

Non-invasive imaging of disrupted protein homeostasis induced by proteasome inhibitor treatment using chemical exchange saturation transfer MRI.

Scientific reports, 2018, 10-10, Volume: 8, Issue:1

Proteasome inhibitors (PIs) are now standard of care for several cancers, and noninvasive biomarkers of treatment response are critically required for early patient stratification and treatment personalization. The present study evaluated whether chemical exchange (CEST) magnetic resonance imaging (MRI) can provide measurements that can be used as the noninvasive biomarkers of proteasome inhibition, alongside diffusion MRI and relaxometry. The sensitivity of human colorectal carcinoma cells to the PI Ixazomib was assessed via in vitro and in vivo dose-response experiments. Acute in vivo response to Ixazomib was assessed at three dosing concentrations, using CEST MRI (amide, amine, hydroxyl signals), diffusion MRI (ADC) and relaxometry (T

Topics: Amides; Amines; Animals; Apoptosis; Boron Compounds; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Diffusion Magnetic Resonance Imaging; Dose-Response Relationship, Drug; Female; Glycine; Humans; Image Interpretation, Computer-Assisted; Magnetic Resonance Imaging; Mice, Nude; Proteasome Inhibitors; Proteostasis; Tumor Burden; Xenograft Model Antitumor Assays

2018